Clostridium difficile carriage in adult cystic fibrosis (CF); implications for patients with CF and the potential for transmission of nosocomial infection

Journal of Cystic Fibrosis

Volumn 16, Issue 2, 2017, Pages 291-298

  Burke, D G ^a   Harrison, M J ^b   Fleming, C ^b   McCarthy, M ^b   Shortt, C ^b   Sulaiman, I ^b   Murphy, D M ^b   Eustace, J A ^c   Shanahan, F ^a   Hill, C ^c   Stanton, C ^d   Rea, M C ^d   Ross, R P ^a   Plant, B J ^b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b Department of Medicine National University of Ireland Cork   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d TEAGASC FOOD RESEARCH CENTRE   (Ireland)

Author keywords

Clostridium difficile; Cystic fibrosis; Nosocomial infection; Transmission

Indexed keywords

AZITHROMYCIN; AZTREONAM; BACTERIAL TOXIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; FUSIDIC ACID; LINEZOLID; MEROPENEM; METRONIDAZOLE; RIFAMPICIN; TOBRAMYCIN; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; CYSTIC FIBROSIS; FECES ANALYSIS; FEMALE; GENE; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTOCLOSTRIDIUM DIFFICILE; RIBOTYPING; BACTERIUM IDENTIFICATION; COHORT ANALYSIS; CROSS INFECTION; HETEROZYGOTE; IRELAND; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PREVALENCE; PROCEDURES; PSEUDOMEMBRANOUS COLITIS;

ADULT; BACTERIAL TYPING TECHNIQUES; CARRIER STATE; CLOSTRIDIUM DIFFICILE; COHORT STUDIES; CROSS INFECTION; CYSTIC FIBROSIS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; IRELAND; MALE; MICROBIAL SENSITIVITY TESTS; PREVALENCE;

EID: 85007285624     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2016.09.008     Document Type: Article

References (56)

1. [1] Leffler, D.A., Lamont, J.T., Clostridium difficile infection. N Engl J Med 373:3 (2015), 287–288.
2. [2] Fekety, R., Shah, A.B., Diagnosis and treatment of Clostridium difficile colitis. JAMA 269:1 (1993), 71–75.
3. [3] Kelly, C.P., Pothoulakis, C., LaMont, J.T., Clostridium difficile colitis. N Engl J Med 330:4 (1994), 257–262.
4. [4] Gerding, D.N., Disease associated with Clostridium difficile infection. Ann Intern Med 110:4 (1989), 255–257.
5. [5] Kuijper, E.J., Coignard, B., Tull, P., Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12:Suppl. 6 (2006), 2–18.
6. [6] Wu, T.C., McCarthy, V.P., Gill, V.J., Isolation rate and toxigenic potential of Clostridium difficile isolates from patients with cystic fibrosis. J Infect Dis, 148(1), 1983, 176.
7. [7] Welkon, C.J., Long, S.S., Thompson, C.M. Jr., Gilligan, P.H., Clostridium difficile in patients with cystic fibrosis. Am J Dis Child 139:8 (1985), 805–808.
8. [8] Peach, S.L., Borriello, S.P., Gaya, H., Barclay, F.E., Welch, A.R., Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis. J Clin Pathol 39:9 (1986), 1013–1018.
9. [9] Pokorny, C.S., Bye, P.T., MacLeod, C., Selby, W.S., Antibiotic-associated colitis and cystic fibrosis. Dig Dis Sci 37:9 (1992), 1464–1468.
10. [10] Yahav, J., Samra, Z., Blau, H., Dinari, G., Chodick, G., Shmuely, H., Helicobacter pylori and Clostridium difficile in cystic fibrosis patients. Dig Dis Sci 51:12 (2006), 2274–2279.
11. [11] Bauer, M.P., Farid, A., Bakker, M., Hoek, R.A., Kuijper, E.J., van Dissel, J.T., Patients with cystic fibrosis have a high carriage rate of non-toxigenic Clostridium difficile. Clin Microbiol Infect 20:7 (2014), O446–O449.
12. [12] Hedsund, C., Gregersen, T., Joensson, I.M., Olesen, H.V., Krogh, K., Gastrointestinal transit times and motility in patients with cystic fibrosis. Scand J Gastroenterol 47:8–9 (2012), 920–926.
13. [13] Dray, X., Bienvenu, T., Desmazes—dufeu, N., Dusser, D., Marteau, P., Hubert, D., Distal intestinal obstruction syndrome in adults with cystic fibrosis. Clin Gastroenterol Hepatol 2:6 (2004), 498–503.
14. [14] Fridge, J.L., Conrad, C., Gerson, L., Castillo, R.O., Cox, K., Risk factors for small bowel bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr 44:2 (2007), 212–218.
15. [15] Lynch, S.V., Goldfarb, K.C., Wild, Y.K., Kong, W., De Lisle, R.C., Brodie, E.L., Cystic fibrosis transmembrane conductance regulator knockout mice exhibit aberrant gastrointestinal microbiota. Gut Microbes, 4(1), 2013, 41.
16. [16] Munck, A., Cystic fibrosis: evidence for gut inflammation. Int J Biochem Cell Biol 52 (2014), 180–183.
17. [17] Duytschaever, G., Huys, G., Bekaert, M., Boulanger, L., De Boeck, K., Vandamme, P., Dysbiosis of bifidobacteria and Clostridium cluster XIVa in the cystic fibrosis fecal microbiota. J Cyst Fibros 12:3 (2013), 206–215.
18. [18] Bruzzese, E., Raia, V., Spagnuolo, M.I., Volpicelli, M., De Marco, G., Maiuri, L., et al. Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Clin Nutr 26:3 (2007), 322–328.
19. [19] Weiss, B., Bujanover, Y., Yahav, Y., Vilozni, D., Fireman, E., Efrati, O., Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Pediatr Pulmonol 45:6 (2010), 536–540.
20. [20] Hoen, A.G., Li, J., Moulton, L.A., O'Toole, G.A., Housman, M.L., Koestler, D.C. et al., Associations between gut microbial colonization in early life and respiratory outcomes in cystic fibrosis. J Pediatr 167:1 (2015), 138–147.
21. [21] Madan, J.C., Koestler, D.C., Stanton, B.A., Davidson, L., Moulton, L.A., Housman, M.L., et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. MBio, 3(4), 2012.
22. [22] Gorbach, S.L., Antibiotics and Clostridium difficile. N Engl J Med 341:22 (1999), 1690–1691.
23. [23] Bartlett, J.G., Chang, T.W., Gurwith, M., Gorbach, S.L., Onderdonk, A.B., Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 298:10 (1978), 531–534.
24. [24] Rabin, H.R., Butler, S.M., Wohl, M.E.B., Geller, D.E., Colin, A.A., Schidlow, D.V., et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 37:15095322 (2004), 400–406.
25. [25] Nakamura, S., Mikawa, M., Nakashio, S., Takabatake, M., Okado, I., Yamakawa, K., et al. Isolation of Clostridium difficile from the feces and the antibody in sera of young and elderly adults. Microbiol Immunol 25:4 (1981), 345–351.
26. [26] Aronsson, B., Mollby, R., Nord, C.E., Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980–1982. J Infect Dis 151:3 (1985), 476–481.
27. [27] Clayton, E.M., Rea, M.C., Shanahan, F., Quigley, E.M.M., Kiely, B., Ross, R.P., et al. Carriage of Clostridium difficile in outpatients with irritable bowel syndrome. J Med Microbiol 61:Pt 9 (2012), 1290–1294.
28. [28] Theunissen, C., Knoop, C., Nonhoff, C., Byl, B., Claus, M., Liesnard, C., et al. Clostridium difficile colitis in cystic fibrosis patients with and without lung transplantation. Transpl Infect Dis 10:4 (2008), 240–244.
29. [29] Dallal, R.M., Harbrecht, B.G., Boujoukas, A.J., Sirio, C.A., Farkas, L.M., Lee, K.K., et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 235:3 (2002), 363–372.
30. [30] Yates, B., Murphy, D.M., Fisher, A.J., Gould, F.K., Lordan, J.L., Dark, J.H., et al. Pseudomembranous colitis in four patients with cystic fibrosis following lung transplantation. BMJ Case Rep, 2009, 2009.
31. [31] Clayton, E.M., Rea, M.C., Shanahan, F., Quigley, E.M.M., Kiely, B., Hill, C., et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 104:5 (2009), 1162–1169.
32. [32] Rea, M.C., O'Sullivan, O., Shanahan, F., O'Toole, P.W., Stanton, C., Ross, R.P., et al. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol 50:3 (2011), 867–875.
33. [33] Smyth, A., Elborn, J.S., Exacerbations in cystic fibrosis: 3 — management. Thorax 63 (2008), 180–184 [England].
34. [34] Drummond, L.J., McCoubrey, J., Smith, D.G., Starr, J.M., Poxton, I.R., Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period. J Med Microbiol 52:Pt 3 (2003), 259–263.
35. [35] Akerlund, T., Alefjord, I., Dohnhammar, U., Struwe, J., Noren, T., Tegmark-Wisell, K., et al. Geographical clustering of cases of infection with moxifloxacin-resistant Clostridium difficile PCR-ribotypes 012, 017 and 046 in Sweden, 2008 and 2009. Eurosurveillance 16:10 (2011), 223–233.
36. [36] Loo, V.G., Bourgault, A.-M., Poirier, L., Lamothe, F., Michaud, S., Turgeon, N., et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 365:18 (2011), 1693–1703.
37. [37] Zilberberg, M.D., Reske, K., Olsen, M., Yan, Y., Dubberke, E.R., Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study. BMC Infect Dis, 14(1), 2014, 306.
38. [38] Health Protection Surveillance Centre, Annual report. 2012.
39. [39] Health Protection Surveillance Centre, Annual report. 2011.
40. [40] Health Protection Surveillance Centre, Annual report. 2010.
41. [41] Health Protection Surveillance Centre, Annual report. 2009.
42. [42] Clabots, C.R., Johnson, S., Olson, M.M., Peterson, L.R., Gerding, D.N., Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 166:3 (1992), 561–567.
43. [43] Shaughnessy, M.K., Micielli, R.L., DePestel, D.D., Arndt, J., Strachan, C.L., Welch, K.B., et al. Evaluation of hospital room assignment and acquisition of Clostridium difficile infection. Infect Control Hosp Epidemiol 32:3 (2011), 201–206.
44. [44] Mitchell, B.G., Dancer, S.J., Anderson, M., Dehn, E., Risk of organism acquisition from prior room occupants: a systematic review and meta-analysis. J Hosp Infect, 2015.
45. [45] McFarland, L.V., Mulligan, M.E., Kwok, R.Y., Stamm, W.E., Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320:4 (1989), 204–210.
46. [46] Curry, S.R., Muto, C.A., Schlackman, J.L., Pasculle, A.W., Shutt, K.A., Marsh, J.W., et al. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis 57:8 (2013), 1094–1102.
47. [47] Stone, S.P., Fuller, C., Savage, J., Cookson, B., Hayward, A., Cooper, B., et al. Evaluation of the national Cleanyourhands campaign to reduce Staphylococcus aureus bacteraemia and Clostridium difficile infection in hospitals in England and Wales by improved hand hygiene: four year, prospective, ecological, interrupted time series study. BMJ, 344, 2012, e3005.
48. [48] Oughton, M.T., Loo, V.G., Dendukuri, N., Fenn, S., Libman, M.D., Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of Clostridium difficile. Infect Control Hosp Epidemiol 30:10 (2009), 939–944.
49. [49] Peláez, T., Alcalá, L., Alonso, R., Rodríguez-Créixems, M., García-Lechuz, J.M., Bouza, E., Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 46:6 (2002), 1647–1650.
50. [50] Peláez, T., Cercenado, E., Alcalá, L., Marín, M., Martín-López, A., Martínez-Alarcón, J., et al. Metronidazole resistance in Clostridium difficile is heterogeneous. J Clin Microbiol 46:9 (2008), 3028–3032.
51. [51] Testing ECoAS, Breakpoint tables for interpretation of MICs and zone diameters version 3.0. valid from 2013 to 01-01 2013 [Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_Breakpoint_table_v_3.0.pdf.
52. [52] Owens, R.C., Donskey, C.J., Gaynes, R.P., Loo, V.G., Muto, C.A., Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 46:Supplement 1 (2008), S19–S31.
53. [53] Johnson, S., Homann, S.R., Bettin, K.M., Quick, J.N., Clabots, C.R., Peterson, L.R., et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 117:4 (1992), 297–302.
54. [54] Hickson, M., D'Souza, A.L., Muthu, N., Rogers, T.R., Want, S., Rajkumar, C., et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ, 335(7610), 2007, 80.
55. [55] van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E.G., de Vos, W.M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:5 (2013), 407–415.
56. [56] Di Nardo, G., Oliva, S., Menichella, A., Pistelli, R., De Biase, R.V., Patriarchi, F., et al. Lactobacillus reuteri ATCC55730 in cystic fibrosis. J Pediatr Gastroenterol Nutr 58:1 (2014), 81–86.